top bottom line ahead estim full year sale ep guidanc rais
humira /ou sale modestli better outlook intact acquisit track
ep estim consensu
ep guidanc rais prior last publish ep
estim review ep guidanc
sale flat estim consensu drug
beat estim includ humira beat ou beat
creon synthroid combin forecast skyrizi
launch sale vs zero model full year skyrizi sale guidanc set
vs estim initi uptak except strong product
forecast includ mavyret full year guidanc vs
estim sevofluoran lupron duodopa kaletra androgel imbruvica
combin light
guidanc humira sale ou guidanc year updat
ou sale expect cer guidanc line estim orilissa full
year sale guidanc set vs estim roll-out endometriosi
slower expect howev long-term outlook remain intact full year
sale guidanc increas cer prior cer estim fx impact
remain last publish revenu estim review
gpm estim
estim sg line forecast net interest/oth
expens forecast pre-tax margin
estim tax rate estim share count
estim updat guidanc item net interest
expens vs prior line item guidanc unchang
upadacitinib /eu approv ra pdufa orilissa file
uterin fibroid come day allergan acquisit close expect
believ ftc risk class also believ opioid
liabil risk complet list event shown follow page
pleas see page report import disclosur
cowen compani
chg total good profit margin royalti profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
cowen compani
time frameev sq levo/carb initi phase parkinson semplic w/bmi phase interim data mmrova-tphas meru data sclc mainten late jaki phase data select- late ii data axial spavencelxta w/rhhbi phase data amliniti phase mm late vela data non-sq nsclc uterin fibroid w/bmi eu approv r/r mm w/poma dex posit chmp juli gazyvaeu approv unfit cll eu approv wmupadacitinib jaki approv ra pdufa acquisitionclos cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
